GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Baijin Life Science Holdings Ltd (HKSE:01466) » Definitions » EBIT

Baijin Life Science Holdings (HKSE:01466) EBIT : HK$-4.63 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Baijin Life Science Holdings EBIT?

Baijin Life Science Holdings's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2024 was HK$1.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was HK$-4.63 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Baijin Life Science Holdings's annualized ROC % for the quarter that ended in Sep. 2024 was 11.01%. Baijin Life Science Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 5.24%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Baijin Life Science Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -0.87%.


Baijin Life Science Holdings EBIT Historical Data

The historical data trend for Baijin Life Science Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baijin Life Science Holdings EBIT Chart

Baijin Life Science Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -271.85 -47.63 -11.08 9.71 -8.25

Baijin Life Science Holdings Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.05 -1.34 -2.22 -6.04 1.40

Competitive Comparison of Baijin Life Science Holdings's EBIT

For the Luxury Goods subindustry, Baijin Life Science Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baijin Life Science Holdings's EV-to-EBIT Distribution in the Retail - Cyclical Industry

For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Baijin Life Science Holdings's EV-to-EBIT falls into.


;
;

Baijin Life Science Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-4.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baijin Life Science Holdings  (HKSE:01466) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Baijin Life Science Holdings's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-5.646 * ( 1 - 369.26% )/( (137.356 + 138.691)/ 2 )
=15.2024196/138.0235
=11.01 %

where

Note: The Operating Income data used here is two times the semi-annual (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Baijin Life Science Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2.806/( ( (19.737 + max(28.946, 0)) + (33.965 + max(24.549, 0)) )/ 2 )
=2.806/( ( 48.683 + 58.514 )/ 2 )
=2.806/53.5985
=5.24 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.037 + 44.34 + 0.029999999999987) - (21.562 + 0 + 8.899)
=28.946

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(26.392 + 48.825 + 10.5) - (53.634 + 0 + 7.534)
=24.549

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Baijin Life Science Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-4.634/530.004
=-0.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baijin Life Science Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Baijin Life Science Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Baijin Life Science Holdings Business Description

Traded in Other Exchanges
Address
66 Gloucester Road, Office B, 9/F Pico Tower, Wanchai, Hong Kong, HKG
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company produces health products that are affordable for the general public. The business segments of the company are Life Science segment which includes cellular technology-based services, provide including cellular drugs R&D, large molecule drugs R&D, clinical research services and R&D and sales on self-owned skincare brand, and Fine Jewelry segment that focuses on the procurement, processing, design, production and wholesale distribution of pearls and fine jewelry products.
Executives
Pacific Wish Limited
Chan Vincent Wing Sing
Hui Ka Man Emily
Su Yaoyao 2201 Interest of corporation controlled by you
Ketto Inform Limited 2101 Beneficial owner

Baijin Life Science Holdings Headlines

No Headlines